CVS Health Corp vs e l f Beauty Inc — how do they compare? CVS Health Corp trades at $86.73 (market cap $112.29B), while e l f Beauty Inc trades at $108.12 (market cap $6.25B). The key difference: CVS Health Corp is far larger — about 18× e l f Beauty Inc's market cap, and CVS Health Corp pays a 3.03% dividend while e l f Beauty Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and e l f Beauty Inc for 25 Days on average.
| CVS | ELF | |
|---|---|---|
Market Cap | $112.29B | $6.25B |
Volume | 7,763,676 | 1,099,552 |
Sector | Health | Consumer Staples |
52-Week High | $110.60 | $144.97 |
52-Week Low | $70.08 | $49.57 |
Typical Hold Time | 83 Days | 25 Days |
Enterprise Value | $174.64B | $6.84B |
Dividend Yield | 3.03% | — |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats in Q1 and Q2 2026, alongside steady revenue growth to $402.07B in 2025, highlight operational strength. The stock's valuation appears attractive with a P/E of 23.17 and P/S of 0.27, while a consensus price target of $111.20 suggests significant upside potential. Positive news includes Aetna's 2027 Medicare plan enhancements and a declared quarterly dividend.
The outlook for CVS remains positive, driven by earnings momentum and strategic initiatives in healthcare services. Key risks include reimbursement pressures and regulatory scrutiny, but Wall Street's 85% buy rating and institutional interest underscore confidence. Investors should weigh the stock's growth prospects against margin volatility and debt levels, with the current price offering a favorable entry point relative to targets.
ELF Beauty trades at $107.95, up 2.78% with bullish technical signals and strong earnings beats. The stock shows robust revenue growth reaching $1.31B in 2025, though net margins compressed to 3.38% in 2026. Recent expansion includes rhode brand launches in Europe via Sephora and innovative marketing through original music albums. Analyst sentiment leans positive with 48% buy ratings despite a consensus price target of $95.91 below current levels.
Outlook remains growth-focused with international expansion driving opportunities, but premium valuation (P/E 108) and margin pressure pose risks. Institutional accumulation and technical strength support near-term upside, though investors should monitor execution on global growth initiatives against high expectations.
Trailing returns across standard periods
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →